Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

Disease progression in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib has been attributed to histologic transformation or acquired mutations in BTK and PLCG2. The rate of resistance and clonal composition of PD are incompletely characterized. We report on CLL patients treate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Ahn, Inhye E., Underbayev, Chingiz, Albitar, Adam, Herman, Sarah E. M., Tian, Xin, Maric, Irina, Arthur, Diane C., Wake, Laura, Pittaluga, Stefania, Yuan, Constance M., Stetler-Stevenson, Maryalice, Soto, Susan, Valdez, Janet, Nierman, Pia, Lotter, Jennifer, Xi, Liqiang, Raffeld, Mark, Farooqui, Mohammed, Albitar, Maher, Wiestner, Adrian
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2017
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5356450/
https://ncbi.nlm.nih.gov/pubmed/28049639
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-06-719294
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados